上海生生冲刺港股IPO！高瓴、君联等位列股东

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange after previously withdrawing its application from the Shanghai Stock Exchange in June 2024 [1] Group 1: Company Overview - Shanghai Shengsheng is a leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry, focusing on clinical trial temperature-controlled supply chain services and extending to commercialized medical product temperature-controlled supply chain services [2] - The company is ranked as the number one temperature-controlled supply chain service provider in China and is the only Chinese company among the top ten global clinical trial temperature-controlled supply chain service providers [2] - The company has served over 7,000 clients, including top biopharmaceutical and biotechnology companies, central laboratories, CROs, and CDMOs [2] Group 2: Operational Capabilities - Shanghai Shengsheng possesses both GMP and GDP qualifications and has established a service network across major cities in China, with over 130 operational sites and more than 40 regional operation centers, covering 99% of prefecture-level cities [3] - The company has also set up regional operation centers in overseas markets, providing services in over 70 countries and regions [3] Group 3: Financial Performance - The company reported revenues of 614.2 million RMB and 654.5 million RMB for the years 2023 and 2024, respectively, with profits of 92.0 million RMB and 26.4 million RMB [4] - For the first three quarters of 2025, the company achieved a revenue of 538.7 million RMB, representing a year-on-year growth of 10.97%, and a profit of 113.0 million RMB, reflecting a year-on-year increase of 68.6% [4] Group 4: Use of IPO Proceeds - The funds raised from the IPO will be used to expand and upgrade the company's domestic and international supply chain service network, enhance temperature control technology and digital capabilities, and support potential strategic investments and acquisitions [4]